What technology area does this patent fall under?

Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.

When was this patent published?

Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Methods for treating cancer using TOR kinase inhibitor combination therapy

US9358232B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9358232-B2
Application number	US-201414254010-A
Country	US
Kind code	B2
Filing date	Apr 16, 2014
Priority date	Apr 17, 2013
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for treating diffuse large B-cell lymphoma, comprising administering an effective amount of a TOR kinase inhibitor in combination with an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide, or a pharmaceutically acceptable salt thereof, to a patient having diffuse large B-cell lymphoma, wherein the TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)-pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)…

Assignees

Signal Pharm Llc

Inventors

Classifications

A61P43/00
Human Necessities · mapped topic
A61P35/02
Human Necessities · mapped topic
A61P35/00
Human Necessities · mapped topic
C07K16/2887
Chemistry & Metallurgy · mapped topic
A61K45/06Primary
Human Necessities · mapped topic

Patent family

Related publications grouped by family.

View patent family 50736199

External sources

Next steps

Free tools are coming soon. Tell us what you want to track and we'll notify you.

Get alerts for this patent View on Google Patents

Request deeper analysis

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9358232B2 cover?: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
Who is the assignee on this patent?: Signal Pharm Llc
What technology area does this patent fall under?: Primary CPC classification A61K45/06. Mapped technology areas include Human Necessities.
When was this patent published?: Publication date Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).